Tag: FIRST@CIRSE
“Excellent” 24-month MOTIV BTK outcomes for bioresorbable scaffold use in below-the-knee...
Presenting data from the MOTIV bioresorbable scaffold (Reva Medical) below-the-knee (BTK) trial during Saturday’s FIRST@CIRSE session at this year’s Cardiovascular and Interventional Radiological Society...
12-month PRISTINE registry data show efficacy of sirolimus-eluting balloon in the...
Tze Tec Chong (Singapore General Hospital, Singapore) presented results from the PRISTINE registry at this year’s Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023...
38th CIRSE annual congress begins this weekend
The European Society of Cardiovascular and Interventional Radiology (CIRSE) will host its 38th annual meeting in Barcelona from September 10 until September 14. Around...
Patients with multiple revascularisations are at higher risk of acute limb...
Symptomatic peripheral arterial disease (PAD) patients undergoing recurrent lower extremity revascularisation have higher rates of ischaemic events, particularly acute limb ischaemia, than those patients...
Calls in Germany for reimbursement as analysis shows drug-eluting technology is...
Stefan Müller-Hülsbeck (Ev Luth Diakonissenanstalt zu Flensburg, Flensburg, Germany) presented attendees of the online meeting of the Cardiovascular and Interventional Radiological Society of Europe...
“No signal of increased risk of long-term mortality” with paclitaxel-coated Luminor...
An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two...
Win for paclitaxel as SAVER registry “reinforces the safety profile” of...
“The SAVER registry reinforces the safety and effectiveness profile for the Stellarex drug-coated balloon (DCB; Philips) in a real-world patient population,” Konstantinos Stavroulakis (St...
24-month AVeNEW study results: Covered stent angioplasty “statistically superior” to angioplasty...
Against the backdrop of increasing end-stage renal disease (ESRD) prevalence in the USA, Bart Dolmatch (Portola Valley, USA) presented the 24-month results of the...
New prediction model for target lesion revascularisation grants “new level of...
“Please feel free to utilise this in your practice,” Michael Dake (University of Arizona Health Sciences, Tucson, USA) urged on the first day of...
